Sens. Settle On 12-Year Exclusivity For Biologics
A U.S. Senate committee has agreed to a proposal that would offer biologic drug manufacturers 12 years of patent exclusivity before allowing competitors to seek regulatory approval to bring follow-on versions...To view the full article, register now.
Already a subscriber? Click here to view full article